Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

To learn if SAR445877 in combination with FOLFOX6 and bevacizumab can be safely given to patients with advanced MSS CRC.

Trial Details

NCT ID
NCT07500298
Phase
PHASE1
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • SAR445877
  • FOLFOX6
  • Bevacizumab
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Eligibility Criteria
  • Ability to understand and willingness to sign informed consent form prior to initiation of the study and any study procedures.
  • Capable of and willing to comply with scheduled visits, treatment plans, laboratory tests, and other study-related tests and procedures.
  • Age ≥18 years.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →